Scientech Research LLC Acquires New Holdings in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)

Scientech Research LLC bought a new position in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm bought 15,377 shares of the biotechnology company’s stock, valued at approximately $374,000. Scientech Research LLC owned 0.06% of Arcturus Therapeutics as of its most recent filing with the SEC.

Other institutional investors have also recently bought and sold shares of the company. Millennium Management LLC lifted its position in Arcturus Therapeutics by 250.1% in the 2nd quarter. Millennium Management LLC now owns 555,024 shares of the biotechnology company’s stock valued at $13,515,000 after acquiring an additional 396,505 shares in the last quarter. Sumitomo Mitsui Trust Holdings Inc. boosted its position in shares of Arcturus Therapeutics by 22.4% during the second quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 1,563,065 shares of the biotechnology company’s stock worth $38,061,000 after buying an additional 286,546 shares during the period. ARK Investment Management LLC grew its holdings in shares of Arcturus Therapeutics by 16.3% during the second quarter. ARK Investment Management LLC now owns 1,964,964 shares of the biotechnology company’s stock worth $47,847,000 after buying an additional 275,315 shares in the last quarter. Nordea Investment Management AB acquired a new stake in Arcturus Therapeutics in the 1st quarter valued at approximately $1,846,000. Finally, Granahan Investment Management LLC lifted its stake in Arcturus Therapeutics by 12.9% in the 4th quarter. Granahan Investment Management LLC now owns 450,366 shares of the biotechnology company’s stock valued at $14,200,000 after acquiring an additional 51,504 shares in the last quarter. Institutional investors own 94.54% of the company’s stock.

Wall Street Analyst Weigh In

ARCT has been the topic of several recent research reports. HC Wainwright lifted their price target on shares of Arcturus Therapeutics from $60.00 to $63.00 and gave the company a “buy” rating in a research note on Thursday, August 8th. Leerink Partnrs upgraded Arcturus Therapeutics to a “strong-buy” rating in a report on Monday, August 12th. Leerink Partners assumed coverage on Arcturus Therapeutics in a research note on Monday, August 12th. They issued an “outperform” rating and a $70.00 price target for the company. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Arcturus Therapeutics in a research report on Monday, September 9th. One research analyst has rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $71.40.

Arcturus Therapeutics Stock Up 1.2 %

Shares of NASDAQ ARCT opened at $22.03 on Monday. Arcturus Therapeutics Holdings Inc. has a twelve month low of $17.52 and a twelve month high of $45.00. The company has a market cap of $593.31 million, a PE ratio of -5.63 and a beta of 2.60. The business’s 50 day moving average price is $20.91 and its two-hundred day moving average price is $26.58.

Arcturus Therapeutics (NASDAQ:ARCT) last posted its quarterly earnings results on Monday, August 5th. The biotechnology company reported ($0.64) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.85) by $1.21. Arcturus Therapeutics had a negative return on equity of 25.47% and a negative net margin of 41.21%. The business had revenue of $49.86 million for the quarter, compared to analysts’ expectations of $21.00 million. During the same quarter in the prior year, the business earned ($1.98) EPS. As a group, research analysts anticipate that Arcturus Therapeutics Holdings Inc. will post -2.6 EPS for the current fiscal year.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.